Medsintez Plant LLC is a modern full-cycle biotechnological enterprise for development and production of pharmaceutical products complying with international GMP requirements and ISO standards. Medsintez plant has been present on the Russian market for 20 years and is an active participant of drug import substitution programs in the Russian Federation.

The company produces genetically engineered and analogue human insulin drugs Rosinsulin®, veterinary insulin drugs, the first Russian drug of recombinant follicle-stimulating hormone for treatment of infertility Primapur®, an innovative direct-acting antiviral drug for treatment influenza, ARVI, COVID-19 Triazavirin®, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.

The company’s products are supplied to all regions of Russia. The production capacity of the plant is able to provide 100% of the country’s needs for vital insulin and FSH drugs, as well as to provide serious support to the country during epidemics and pandemics of RNA viral infections.

One of the directions for development of the Medsintez plant is contract manufacturing, including the production of products under the customer’s trademark. Among the partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, etc.

15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia. Тel.: +7 (34370) 2-50-61.

E-mail: medsintez@mail.ru